Pharmacological activation of the p53 pathway in haematological malignancies.
about
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma developmentImmunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor MicroenvironmentThe insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potentialTargeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myelomaSignificant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug TreatmentInhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationp53 abnormalities and potential therapeutic targeting in multiple myeloma.Targeting p53 by small molecules in hematological malignancies.Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumorsMicroRNAs: New Players in Multiple Myeloma.Myc, Aurora Kinase A, and mutant p53(R172H) co-operate in a mouse model of metastatic skin carcinoma.Systematic analysis of berberine-induced signaling pathway between miRNA clusters and mRNAs and identification of mir-99a ∼ 125b cluster function by seed-targeting inhibitors in multiple myeloma cellsDrug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.TPEN induces apoptosis independently of zinc chelator activity in a model of acute lymphoblastic leukemia and ex vivo acute leukemia cells through oxidative stress and mitochondria caspase-3- and AIF-dependent pathways.The p53 tumor suppressor protein regulates hematopoietic stem cell fate.Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.The miRNA network: micro-regulator of cell signaling in cancer.New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy.Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).A preliminary study of the effect of curcumin on the expression of p53 protein in a human multiple myeloma cell line.Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents.p53 haploinsufficiency and functional abnormalities in multiple myeloma.RITA enhances chemosensivity of pre-B ALL cells to doxorubicin by inducing p53-dependent apoptosis.Nutlin's two roads toward apoptosis.Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).Vitamin K3 and vitamin C alone or in combination induced apoptosis in leukemia cells by a similar oxidative stress signalling mechanism.Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis.MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options?
P2860
Q24628811-5C3CB6BC-6218-43CD-A0C5-8E4000D5E31FQ28071935-C62DF889-14AE-4BBF-9723-7FD1433A60D4Q28075927-F777B051-5B1E-4E2D-8174-73C8C9A810E6Q28479002-7CC578CE-0AF2-4451-B792-8CCE4A2413A2Q28548249-A8FCE534-92A0-4F4F-A45F-79BB92580CBAQ28589774-C2E23589-02D3-48FE-9AA4-37B9558B891BQ33731216-EA318014-86F4-4334-9FDB-53A0AB660B88Q33852683-8DF8E75C-7D8F-4154-BB95-7ADB327166D6Q34636996-30B3A4DB-7C30-4092-9D3C-F9641BBE8873Q35064987-94C0C02F-7124-44D8-A836-25BA134DDEB2Q35711092-5ECB184E-66BF-40FF-A9A5-7A511CAE251CQ36078222-0EDE3091-FD12-4329-A1F4-A16D7F4C8C20Q36189632-8E06503E-7D9E-4463-AC59-1075E78A1872Q36312897-CBA6D5C9-5A4D-4E35-B7E7-9AF00C37A610Q36520787-0A9006CB-C4DB-46E9-A6E8-5D6948D2E847Q37887629-70B73607-6269-48DD-8B59-259FC8FE3F7AQ38059739-C4831AB5-C7A5-4ED9-B3EB-B145F3C185EDQ38243969-761DB695-ADBB-4321-BB7D-26D39E15973BQ38389967-338AE266-6EF8-4598-AE09-224F2D04EFFFQ38784989-94C3CD18-EAE6-4B4F-8718-41616E98E302Q38897664-A312A9FD-9637-4CF0-BEE9-1AB9C0E8CD99Q39009323-476DAC5B-2C1C-4D52-BD2B-7EA4464124B0Q39015919-C734FFA2-CDFC-44F1-9FA2-549431B24C12Q39506861-846349D3-7A95-4B8A-ADCA-5269B8F89A86Q39666504-79BDD41E-9BB5-4A3A-9928-958412F3334BQ39685958-21097A4E-FED9-41F9-95BE-415F553B6851Q40614153-6AD76381-444B-45A6-A9F9-9276C906841FQ42008304-76DB1358-A389-42A6-98BA-DA9C6A7B02F8Q44027685-9FE61241-B7BE-4C00-8264-C24F99FD26DFQ52340395-F09A4189-9EEB-44A2-80AD-F77A771B27E3
P2860
Pharmacological activation of the p53 pathway in haematological malignancies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacological activation of the p53 pathway in haematological malignancies.
@en
Pharmacological activation of the p53 pathway in haematological malignancies.
@nl
type
label
Pharmacological activation of the p53 pathway in haematological malignancies.
@en
Pharmacological activation of the p53 pathway in haematological malignancies.
@nl
prefLabel
Pharmacological activation of the p53 pathway in haematological malignancies.
@en
Pharmacological activation of the p53 pathway in haematological malignancies.
@nl
P2093
P356
P1476
Pharmacological activation of the p53 pathway in haematological malignancies.
@en
P2093
Hong Chang
Johann Micallef
Manujendra N Saha
P304
P356
10.1136/JCP.2009.070961
P407
P577
2009-12-02T00:00:00Z